Nordic Nanovector, an Oslo, Norway-based biotechnology company focused on hematology and oncology, has formed a collaboration with Heidelberg Pharma, the Ladenburg, Germay-based subsidiary of the Munich, Germany-headquartered biopharmaceutical company, Wilex, which specializes in antibody-drug conjugates (ADCs), to develop ADCs for treating leukemias. This collaboration is part of Nordic Nanovector’s strategy to develop its pipeline in ADCs. Financial term of the deal were not disclosed.

Source: Nordic Nanovector